Navigation Links
Anaphore Announces Acquisition of RuiYi in Shanghai China for GPCR Biologics Drug Discovery Platform

LA JOLLA, Calif., March 22, 2012 /PRNewswire/ -- Anaphore Inc. today announced that it has acquired Shanghai-based RuiYi Inc., bringing the company a powerful biologics drug discovery platform focused on the discovery and development of biologic therapies targeting G protein coupled receptors (GPCRs).  RuiYi was founded by Raymond Stevens, PhD., of The Scripps Research Institute (TSRI) and TSRI alumni Fei Xu, Ph.D. of Shanghai, China.

"The acquisition of RuiYi in China allows Anaphore to access the substantial scientific expertise, capital and potential new collaboration opportunities in the Chinese pharmaceutical marketplace," said Paul A. Grayson, president and CEO of Anaphore.  "RuiYi also provides Anaphore a Wholly Foreign-Owned Enterprise (WFOE) in Pudong Shanghai, a necessity for conducting business in China, and establishes relationships with all of RuiYi's current collaborators."

"I am very excited about the opportunity to work with Paul and his creative team at Anaphore," added Dr. Stevens.  "Anaphore's existing expertise in biologic drug development combined with RuiYi's knowledge in targeting GPCRs is an optimal alignment of talent, energy and resource to discover novel medicines to address human medical needs."

GPCRs are a class of cell surface signaling proteins that has broad tissue expression in the body and are ideal drug targets, constituting greater than 40 percent of marketed small molecule drugs. While much progress has been made over the years in the development of small molecule pharmaceuticals targeting GPCRs, development of biologic therapies have been much more limited. RuiYi's technology allows for the discovery of high quality GPCR biologics.

New Members of Anaphore Board of Directors

Anaphore is also announcing two new independent directors to its Board of Directors – Peppi Prasit and Raymond Stevens.  "We are delighted to bring both Peppi and Ray onto the Anaphore Board of Directors," commented Paul Grayson.  "Combining the substantial and proven scientific and drug-hunting capabilities of both Ray and Peppi enhances the expertise of our existing board and investor base."

Peppi Prasit, PhD, is the founder and CEO of Inception Sciences. Previously, he was the co-founder and chief scientific officer of San Diego-based Amira Pharmaceuticals, which was acquired by Bristol Myers Squibb in July 2011. Dr. Prasit has more than 20 years of experience in pharmaceutical research and management serving in various positions with Merck Frosst Canada and more recently at Merck San Diego. During this time, he played a pivotal role in the discovery of multiple marketed drugs.  Dr. Prasit received his B.Sc. from UCL, London University, and his Ph.D. from Victoria University of Wellington in New Zealand and served as a postdoctoral fellow at Princeton University.

Raymond Stevens is a Professor of Molecular Biology and Chemistry at The Scripps Research Institute in La Jolla, California.   Dr. Stevens obtained his Ph.D. in chemistry in 1988 and conducted his post-doctoral research in structural biology in the Chemistry Department at Harvard University. Dr. Stevens has helped to pioneer the areas of high throughput structural biology and GPCR structure-function, publishing more than 270 peer reviewed publications in the past 20 years.  His research is focused in the area of structural biology and structure based drug discovery including involvement in the development of TamifluTM for influenza virus, KuvanTM for mild phenylketonuria, Peg-palTM for classical phenylketonuria, and alogliptin for type II diabetes.  He has also founded four biotech companies - Syrrx, MemRx, Receptos, and RuiYi.

Anaphore recently closed on the fifteen million dollar second tranche of the company's thirty eight million dollar Series A financing.  Investors in the financing, which had its first close in January 2009, included 5AM Ventures, Versant Ventures, Apposite Capital, SR One, Merck Serono Ventures and Aravis.

About Anaphore

Anaphore is developing protein pharmaceuticals to address significant unmet medical needs for patients with serious diseases.

For more information please visit

About RuiYi

RuiYi is a Wholly Foreign-Owned Enterprise (WFOE) located in the Zhangjiang Hi-Tech Park in Pudong Shanghai, China. RuiYi is developing biologic therapies that target G protein coupled receptors (GPCRs).

For more information please visit


SOURCE Anaphore Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anaphore Appoints Michael F. Haller, Ph.D., Senior Vice President of Strategic Partnerships and H Casey Logan Senior Vice President of Business Development
2. Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma to Develop and Commercialize Novel Protein Pharmaceuticals for Autoimmune Disorders
3. Tanabe Research Labs Enters R&D Partnership with Anaphore to Develop Novel Protein Pharmaceuticals for Autoimmune Disorders
4. Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 Antibody
5. Millennium Laboratories Announces Laboratory Responsibility Pledge
6. iBio Announces Successful Completion of H1N1 Influenza Vaccine Phase 1 Clinical Trial
7. Faruqi & Faruqi, LLP Announces Investigation of ZELTIQ Aesthetics, Inc.
8. Sunpeaks Ventures Announces Clotamin to be Sold at Navarro Discount Pharmacies
9. OriGene Technologies Announces the Release Specificity-Verified UltraMAB™ Antibodies
10. HUYA Bioscience Announces New Partnership with a High Profile Pharmaceutical Lab at Shanghais Prestigious Fudan University
11. Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results
Post Your Comments:
(Date:10/13/2015)... 13, 2015  Synapse Biomedical Inc. ( ) ... (PAS) studying the use of the NeuRx ® ... enroll patients. the United States ... market-approved criteria. The PAS study group met their initial ... study has since expanded the enrollment target to 150 ...
(Date:10/13/2015)... 2015  SeraCare Life Sciences, a leading partner to ... company,s precision medicine business unit has launched its second ... next-generation sequencing (NGS)-based tumor profiling assays.  The Seraseq TM ... mixture of mutations in key oncogenes and tumor suppressor ... , but is offered at five additional allele frequencies. ...
(Date:10/13/2015)... , Oct. 13 2015 ... the addition of the "US & ... 16 Countries (2010-2021)" report to their ... announced the addition of the "US ... - 16 Countries (2010-2021)" report to ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... , ... The added calories and sugar in an average trick-or-treat bag may ... to do? Registered dietitians from Retrofit , the leading corporate weight management program, ... , “Halloween is a high-calorie holiday,” said Dara Aronow, Registered Dietitian, Retrofit. “Use this ...
(Date:10/13/2015)... ... ... The American Institutes for Research ( AIR ) developed a collection of ... experienced sexual assault and other trauma. The toolkit, funded by the U.S. Department of ... Act's 21st anniversary. , AIR developed the Safe Place toolkit ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... enterprise focused on cancer patients, today announced a new partnership with the ... battling this rare type of non-Hodgkin’s lymphoma, their families and physicians. , ...
(Date:10/13/2015)... ... October 13, 2015 , ... PhyMed Healthcare Group , ... its partnership with WPC Healthcare , a provider of predictive analytics solutions ... data into an aggregated data repository necessary to perform reporting and analytics on ...
(Date:10/13/2015)... ... 13, 2015 , ... ProText Kinetic Panel is a typography creation tool made ... can create energetic text animations in any layout without the use of keyframes. Using ... timeline and stylize the text. With intuitive on-screen controls, users can re-position and scale ...
Breaking Medicine News(10 mins):